Yesseinia I. Angleró-Rodriguez

Development of an investigational epigenetic silencer therapy to transcriptionally inactivate viral DNA in chronic hepatitis B

Approved chronic hepatitis B therapies rarely result in functional cure, as they fail to permanently silence all transcriptionally active hepatitis B virus (HBV) DNA. CRMA-1001 employs an optimized epigenetic silencer that represses viral transcription through targeted deposition...